WeightWatchers’s (NASDAQ:WW) Q2 CY2026: Beats On Revenue

WeightWatchers (NASDAQ:WW) reported Q2 CY2026 revenue of $162.3 million, down 14.2% year on year, but 2% above Wall Street estimates, according to the company. Full-year revenue guidance is $627.5 million at the midpoint, 0.7% below analysts’ estimates. GAAP profit was $1.41 per share above consensus; shares fell 1.3% to $15.23 after the report.

Original reporting
Published Aug 5, 2026, 9:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 5, 2026, 9:44 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
WeightWatchers’s (NASDAQ:WW) Q2 CY2026: Beats On Revenue — source image
Decision brief

The 30-second read

$WWNeutralMed
01

Why it matters

Q2 results were mixed: revenue beat by 2% versus estimates and GAAP EPS beat, but full-year revenue guidance at $627.5M midpoint was 0.7% below analysts and operating margin contracted sharply. Free cash flow turned positive in Q2, but the longer-term FCF margin history remains negative, keeping investor focus on sustainability.

02

Market read

Traders can reassess WW’s near-term earnings power and cash generation trajectory after the reported beat/miss mix and the immediate post-report stock drop.

03

What to watch

The article notes operating margin fell to 5.8% and FCF margin averaged negative over two years; traders should separate one-quarter seasonality from the longer-term cash burn trend.

Relevance 7/10Novelty 6/10Timing: after-hours/next-session setup following Q2 results and immediate post-report stock move

Background

WeightWatchers is a consumer wellness company focused on weight-loss products and services; the article frames its recent demand weakness and profitability/cash-flow trends.

Company-level read

Ticker impact

$WWNeutralMedium confidence
Context

WeightWatchers reported Q2 CY2026 revenue of $162.3M, down 14.2% YoY, but beating estimates by 2%, while full-year revenue guidance missed by 0.7%.

Expected impact

Near-term volatility likely, with downside risk if investors focus on shrinking demand and slightly soft guidance despite the EPS/revenue beat.

Evidence & confidence

The article provides concrete datapoints (revenue beat, guidance miss, operating margin contraction, and FCF turning positive but still volatile) that can drive trading around the earnings reaction.

Market effects

Consumer wellness and weight-loss services may see read-through on demand durability and margin pressure versus peers.

No specific regional spillover described beyond US-listed consumer discretionary sentiment.

Limited global relevance; story is company-specific with no cross-border catalysts mentioned.

Counterpoint

The positive free cash flow inflection in Q2 (FCF $30.06M) could indicate operating leverage improving, making the guidance miss less concerning than it appears.

Key entities

  • WeightWatchers

    Reported Q2 CY2026 revenue and GAAP EPS, plus full-year revenue guidance, and discussed operating margin and free cash flow trends.

Related articles

$WWMed

WW International Q2 Earnings Call Highlights

WW International (NASDAQ:WW) reported Q2 average revenue per user up 10.2% YoY. Clinical subscription revenue rose 30.4% to $39.9M, while behavioral fell 22.7% to $121.5M. Gross margin was 70.3% (adjusted 73.6%). WW ended with $101.5M cash, repaid debt, and reaffirmed 2026 revenue $620M-$635M and adjusted EBITDA $105M-$115M.

$WWMed

WW INTERNATIONAL, INC. (WW): Results of Operations and Financial Condition

WW INTERNATIONAL, INC. (WW) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d15116dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Weight Watchers Announces Second Quarter 2026 Results Total End of Period Subscribers of 2.5 million; End of Period Clinical Subscribers of 197 thousand, up 55.7% year-over-year Core+ End of Period Subscribers of 541 thousan

$WWMedAI 8/10

Why WeightWatchers (WW) Stock Is Trading Up Today

WeightWatchers (NASDAQ: WW) shares rose 6.3% in the afternoon after the company said its Weight Watchers Med+ program is now available through Eli Lilly’s digital platform, LillyDirect. The program pairs GLP-1 prescription obesity drugs with behavioral, nutritional, and lifestyle support. The stock is down 45.5% year to date, at $17.13.

$CPTMedAI 8/10

Camden Property Trust (CPT) Q2 2026 Earnings Call Transcript

Camden Property Trust (CPT) discussed its Q2 2026 earnings call, focusing on exiting its California multifamily portfolio. According to management, it sold the 19-year-old California portfolio for $1.625 billion, with trailing 12-month FFO and AFFO yields of 5.6% and 5.2%. Camden repurchased $694 million of shares and closed $645 million of acquisitions plus $195 million of awarded acquisitions, reaffirming $6.75/share FFO guidance.

$UNITMed

Uniti (UNIT) Q2 2026 Earnings Call Transcript

Uniti (UNIT) held its Q2 2026 earnings call, saying demand was strong across categories and highlighting growth in fiber revenue. The company reported total fiber revenue up 10% year over year and Fiber Infrastructure fiber revenue up 6%. Uniti raised its 2026 outlook for new fiber homes to 475,000 to 525,000 and said managed services attachment rose, with 16% of new bookings including it.

$WENMed

Here's why Wendy's is losing the burger wars

Wendy’s (WEN) reported Q2 earnings and said traffic is down, value has slipped, and franchisee economics face pressure, according to CEO Bob Wright. Same-store sales fell 6.3% in the latest quarter for six straight declines. Wright cited quality degradation and an overly complex Biggie value menu, and said the company will rebuild ingredients and pricing. The stock is about $7.70.